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Abstract
Background: For the treatment of depression in diabetes patients, it is important that depression is recognized at
an early stage. A screening method for depression is the patient health questionnaire (PHQ-9). The aim of this
study is to validate the 9-item Patient Health Questionnaire (PHQ-9) as a screening instrument for depression in
diabetes patients in outpatient clinics.
Methods: 197 diabetes patients from outpatient clinics in the Netherlands filled in the PHQ-9. Within 2 weeks they
were approached for an interview with the Mini Neuropsychiatric Interview. DSM-IV diagnoses of Major Depressive
Disorder (MDD) were the criterion for which the sensitivity, specificity, positive- and negative predictive values and
Receiver Operator Curves (ROC) for the PHQ-9 were calculated.
Results: The cut-off point of a summed score of 12 on the PHQ-9 resulted in a sensitivity of 75.7% and a
specificity of 80.0%. Predictive values for negative and positive test results were respectively 93.4% and 46.7%. The
ROC showed an area under the curve of 0.77.
Conclusions: The PHQ-9 proved to be an efficient and well-received screening instrument for MDD in this sample
of diabetes patients in a specialized outpatient clinic. The higher cut-off point of 12 that was needed and
somewhat lower sensitivity than had been reported elsewhere may be due to the fact that the patients from a
specialized diabetes clinic have more severe pathology and more complications, which could be recognized by the
PHQ-9 as depression symptoms, while instead being diabetes symptoms.
Background
Seven percent of adults in the USA have been diagnosed
with Major Depressive Disorder (MDD) and in adults
with chronic diseases, such as diabetes, this increases to
over eleven percent [1]. Although the causal connection
between the two remains unclear, the consequences are
far-reaching. Having both diabetes and depression is
associated with poor glycaemic control, resulting in
more severe complications and a lower quality of life
[2,3]. With the increasing severity of diabetes, the preva-
lence of depression also increases, and especially in
vulnerable patients such as those with diabetes-related
complications. Depression has severe consequences;
underlining the importance of focus on the prevention
of depression.
Depression often remains unrecognized, and although
several screening questionnaires are available, unfortu-
nately, most questionnaires have been validated for use
in primary care in patients with less complex medical
illnesses. It is expected that patients with severe diabetes
and depression are frequently present in specialized out-
patient clinics or hospitals, but specialists often do not
have the necessary time or skills to recognize depres-
sion. The recognition of depression is very important
and the Patient Health Questionnaire (PHQ-9) was
developed for this purpose [4,5]. This instrument has
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already been validated for primary care patients, cardiac
patients in general hospitals [6], and diabetes patients in
primary care [7], but not for diabetes patients in specia-
lized outpatient clinics. Besides that, the present study is
the first one assessing operating characteristics for the
PHQ-9 in diabetes patients. In patients with chronic
medical diseases, co-morbid MDD can be difficult to
identify, because the symptoms of the two may overlap.
The effect of symptom overlap on the performance of
screening instruments for depression, such as the PHQ-
9 [4], would be that higher cut-off points are necessary
to correctly identify MDD in the chronically ill than in a
population with less severe illnesses. The overall effect
would be that both sensitivity and specificity would
decline.
In this study we assessed the criterion validity, in
terms of sensitivity, specificity, positive and negative pre-
dictive value. What is new is that Receiver Operator
Curves (ROC) were assessed of the PHQ-9 for MDD in
diabetes patients in specialized outpatient clinics. These
specialized clinics differ from general diabetic care
clinics in that in these specialized clinics foremost
patients with severe diabetes with complications are pre-
sent and specialized clinical diabetes care is provided by
a team of a diabetologist, a specialized diabetes nurse
and a dietician.
Methods
Patients and procedures
After approval of the study protocol by the Medical
Ethics Committee “Verenigde commissies mensgebon-
den onderzoek”, patients were selected from two specia-
lized outpatient clinics for diabetes in the east of the
Netherlands.
After giving informed consent, the patients received
the PHQ-9 by mail. Those who gave informed consent
had a MIni Neuropsychiatric Interview (MINI) by tele-
phone [8], within two weeks after filling in the PHQ-9.
The interviews were administered by trained inter-
viewers who were not blinded for the PHQ-9 scores.
Patients were excluded if we were unable to contact
them within two weeks after they had filled in the
PHQ-9 or if they did not give informed consent.
Measurements
The PHQ-9 is a screening questionnaire, developed by
Kroenke et al [4] containing nine questions about the
symptoms of MDD. It has the following answer cate-
gories: “not at all”, “various days”, “more than half the
days” and “almost every day”. Respectively zero, one,
two or three points were scored and a summed score of
the nine questions was calculated. The questions refer
to the situation in the previous two weeks. This ques-
tionnaire is based on the Diagnostic and Statistic
Manual of mental disorders-IV (DSM-IV) criteria for
diagnosing MDD in patients with medical illnesses, and
the questions concerning fatigue, concentration, depres-
sive complaints, thoughts of death, etc. The PHQ-9 can
also be used to screen patients for MDD specifically,
according to the DSMIV criteria. This ‘algorithm’, devel-
oped by Kroenke et al [4] is positive for MDD when a
total of five questions on the PHQ-9 have a score of
two or more points, with exception for question nine:
scoring at least 1 point is sufficient. Besides that, ques-
tion one ("in the past two weeks I had less interest and
fun in doing activities”), or question two ("in the past
two weeks I felt dejected, depressed or desperate”), have
to be answered positively.
In this study, the telephone based MINI [8] was used
as the criterion instrument to diagnose MDD. The ques-
tions in this interview, which are often used in clinical
practice, are based on the DSMIV criteria.
Data-analyses
The criterion validity of the PHQ-9 was analyzed in
terms of sensitivity, specificity, and positive and negative
predictive values for different cut-off scores. As shown
in Table 1, sensitivity is the proportion of those with
MDD, according to the MINI who are correctly
screened out by the PHQ (a/a+c). Specificity is the pro-
portion of those without MDD, according to the MINI,
who are correctly identified as such by the PHQ (d/b
+d). The positive predictive value is the proportion of
those with a positive (elevated) PHQ-9 score who have
MDD according to the MINI (a/a+b). The negative pre-
dictive value is the proportion of those with a negative
(normal) PHQ-9 score who do not have MDD (d/d+c),
as shown in table 1.
There is always a possibility that a patient is falsely
screened positive or negative. Therefore, it is important
to reduce this possibility by identifying the most optimal
combination of sensitivity and specificity. This way, the
clinically acceptable risk of a falsely screened patient can
be determined.
When a higher criterion value is selected, the false
positive fraction will decrease with increased specificity
Table 1 Sensitivity and specificity calculations
Clinical diagnosis Test result
MINI positive MINI negative Total
PHQ-9 positive A B A+B
PHQ-9 negative C D C+D
Total A+C B+D A+B+C+D
Sensitivity = A/(A+C)
Specificity = D/(D+B)
Predictive value (positive test results) = A/(A+B)
Predictive value (negative test results) = D/(D+C)
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but on the other hand the true positive fraction and
sensitivity will decrease, as described by Zweig et al [9]:
“In a Receiver Operating Characteristic (ROC) curve
the true positive rate (Sensitivity) is plotted in function of
the false positive rate (100-Specificity) for different cut-
off points. Each point on the ROC plot represents a sen-
sitivity/specificity pair corresponding to a particular deci-
sion threshold. A test with perfect discrimination (no
overlap in the two distributions) has a ROC plot that
passes through the upper left corner (100% sensitivity,
100% specificity). Therefore the closer the ROC plot is to
the upper left corner, the higher the overall accuracy of
the test” [9]. The flattening of the curve shows when
there is no additional benefit of the screening method.
To answer the research question on the criterion
validity of the PHQ-9 a Receiver Operating Characteris-
tic curve (ROC curve) is made with SPSS version 15.0.
Results
Of the 1,278 patients that filled in the PHQ-9, 382 were
excluded because they did not give informed consent
and another 501 were excluded because they did not
return the PHQ-9 within 2 weeks. Of the 395 eligible
patients, 198 were unable to be reached within 2 weeks
after they had filled in the PHQ-9, so data on 197 parti-
cipants were finally included in our analyses (49.8% of
the eligible patients).
The mean age of the study sample (N = 197) was
61.82 years (SD = 13.69), 96 participants were female
(48.7%) and 101 were male (51.3%). 106 patients (53.8%)
scored negative on the PHQ-9 and 91 (46.2%) scored
positive on the PHQ-9. The mean PHQ-9 score was
7.95 (SEM = 0.46). There were a total of 197 MINIs,
81.2% were negative for MDD (N = 160) and 18.8%
were positive for MDD (N = 37). The baseline charac-
teristics of these patients are shown in Table 2.
Table 3 shows the sensitivity, specificity, and predic-
tive values for both positive and negative test results for
a selected number of summed PHQ-9 scores. These
were calculated for summed scores from 0 to 27, but a
range of summed scores from 8 to 12 showed the most
optimal results, and are therefore presented here.
The requirements for a screener can vary, but for most
purposes the lower boundary of the sensitivity of a
screener is around the 75%. Table 3 shows that a cut-off
point of 12 combines sensitivity > 75% with the optimal
specificity (80%). Lower cut-off points by definition
improve the sensitivity, with a sensitivity of 91.9% for the
summed scores of 8, 9 or 10 on the PHQ-9. This is at
the expense of the efficiency of the screening; a lower
specificity varying from 59.4% for a cut-off score of 8, to
74.4% for a cut-off score of 11. Predictive values for the
test-positive results varied from 34.4% for a cut-off score
of 8, to 46.7% for a cut-off score of 12. The predictive
values for the test-negative results increased from 96.9%
for a cut-off score of 8, to 97.2% for a cut-off score of 10,
and then decreased to 93.4% for the cut-off score of 12.
Table 4 shows the results of the validation of the algo-
rithm score of the PHQ-9. We found a sensitivity of
58.3% and a specificity of 86.9%. Predictive values for
positive and negative test results were respectively 50.0%
and 90.3%.
The ROC curves, calculated for the PHQ-9 summed
score are shown in Figure 1. The calculated area under
Table 2 Baseline characteristics
Age (Mean, sd)
Years 61.82 (13.69)
Gender (freq, %)
Female 96 (48.7)
Male 101 (51.3)
PHQ-9 score (mean, std. error)
0-27 7.95 (0.46)
0-10 “negative” 2.78 (0.27)
>10 “positive” 14.02 (0.41)
Algorithm score (N, %)
Negative 154 (78.2)
Positive 43 (21.8)
MINI (N, %)
Negative 160 (81.2)
Positive 37 (18.8)
Hospital(N, %)
ZGT Almelo 166 (84.3)
ZGT Hengelo 31 (15.7)
Table 3 Sensitivity, specificity, predictive values and efficiency outcomes for different cut-off scores
Score ≥8 Score ≥9 Score ≥10 Score ≥11 Score ≥12
Occurrence N = 99 (50.3%) N = 95 (48.2%) N = 91 (46.2%) N = 71 (36.0%) N = 60 (30.5%)
Sensitivity 91.9% 91.9% 91.9% 81.1% 75.7%
Specificity 59.4% 61.9% 64.4% 74.4% 80.0%
PV (pos. t.) 96.9% 97.1% 97.2% 94.4% 93.4%
PV (neg. t.) 34.3% 35.8% 37.4% 37.4% 46.7%
Efficiency 49.8% 51.8% 53.8% 63.9% 69.5%
(Abbreviations: PV, predictive value; neg. t, negative test results; pos. t., positive test results)
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the curve (AUC) for the PHQ-9 summed score versus
MINI was 0.77 (SE = 0.04; 95%CI = 0.69 - 0.84). The
calculated AUC and CI scores are shown in Table 5.
These values are significant.
Discussion
Findings of the study
In this study, for the first time the PHQ9 is validated as
a screening instrument for MDD in diabetes patients
visiting a specialized outpatient clinic. As such, it gives
us important information about the validity and appro-
priate cut off scores for identifying Diabetes patients
with a high possibility for having MDD.
The main finding of this study is that the PHQ-9
appears to have satisfactory criterion validity as a
screening instrument for MDD in diabetes patients in
specialized outpatient clinics. We recommend using a
cut-off score of 12 to recognize depression in diabetes
patients from specialized outpatient clinics. This is a
higher cutoff score than is generally used for identifica-
tion of MDD patients in the primary care setting in
patients without advanced medical co-morbidity.
The predictive value in general does not only depend
on the quality of the instrument, but varies with the
prevalence of the disorder in the study population and
with factors that may blur diagnosis and cause misclassi-
fication of those who are at risk for the diagnosis. In the
present sample, the a priori likelihood of patients having
MDD was relatively high (18,8%), while their often com-
plex medical condition might tend to blur the contrast
between those with and without depression. The conse-
quence is that one would expect screening instruments
for depression to perform less efficiently, and that
Table 4 Sensitivity, specificity, predictive values and
efficiency outcomes for the algorithm score
PHQ 0-27 PHQ > 10
Occurrence * N = 91
pos. algorithm N = 42 (21.3%) N = 42 (46.2%)
neg. algorithm N = 155 (78.7%) N = 49 (53.9%)
Sensitivity 58.3% 63.6%
Specificity 86.9% 63.8%
PV (pos. t.) 50.0% 50.0%
PV (neg. t.) 90.3% 75.5%
Efficiency 78.7% 53.9%
*consists of all participants, N = 197
(Abbreviations: pos. algorithm, positive algorithm; neg. algorithm, negative
algorithm; PV, predictive value; neg. t, negative test results; pos. t., positive
test results)
Figure 1 ROC curve for PHQ-9 vs. MINI and Algorithm vs. MINI. (Note: the dotted line is the reference line)
Table 5 Outcomes of AUC for the PHQ-9 summed score
versus the MINI
Asymptotic 95% Confidence
Interval
Test result: AUC SEa Lower bound Upper bound
PHQ-9 summed score 0.77 0.04 0.69 0.84
a Under the nonparametric assumption
(Abbreviations: AUC, area under curve; SE, standard error)
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higher cut-off points are necessary to efficiently elimi-
nate those with depression. This proved to be the case.
The algorithm score, although it literally follows the
DSMIV criteria, did not show very good sensitivity or
specificity (resp. 63.8% and 63.6%). This is unexpected,
because the MINI interview, used in this study to diag-
nose MDD, also follows the DSMIV criteria.
Limitations of the study
Limitations of this study were first of all that it was
not possible to blind the interviewers with regard to
the PHQ scores. Although they were not aware of the
purpose of the interview, knowing the scores might
have influenced the outcomes, and might also have
inflated both sensitivity and specificity. Secondly, the
response rate was not high, because only patients who
returned the PHQ-9 within two weeks after receiving
it were included. Unfortunately, no epidemiological
data on the non responders could be obtained, as this
was confidential information which the hospitals were
not allowed to provide. Therefore, the findings of this
study cannot be extrapolated to the general population
as no indication can be made of the characteristics
of the non-responders. However, this study was not
intended to give information for the use of the
screener in the broad population, but for the validity
of the pHQ9 as a screener in patients with Diabetes
visiting specialized diabetes clinics. For this purpose,
the findings are very relevant.
Also, the telephone response of almost 50% might
seem low, but this is an average response rate on epide-
miologic research in the Netherlands.
Thirdly, there could be up to a 2-week lag between
administration of the PHQ-9 and the MINI. During this
time, higher PHQ-9 scores might have “regressed to the
mean” thus meaning higher cut-off points might have
been needed to correspond to depressive disorder diag-
noses than if the PHQ-9 and MINI had been adminis-
tered more closely in time.
Our findings correspond with the results of other stu-
dies. A cut-off point of ≥10 was found to be the optimal
cut-off point with high sensitivity and specificity scores
(respectively 91% and 89% for MDD) in stroke patients
[10]. In a study in which depression was assessed in
patients with traumatic brain injury, an optimal cut-off
point of ≥10 with a sensitivity of 93% and a specificity
of 89% was also reported [11]. In several studies per-
formed in the medically ill, an optimal cut-off score of
12 was recommended [12,13]. One reason why we
found that a higher cut-off point was optimal for
patients with diabetes may be that the symptoms of
MDD and diabetes can overlap.
Conclusions
Looking closer at our results, a cut-off point of ≥10 or
≥12 can be used, depending on the purpose of the
screening. If the main purpose is screening for patients
with depression in a clinical setting, a cut-off point of
≥12 can be recommended because of its higher specifi-
city. The probability that a patient is falsely screened as
depressed is then at an acceptable rate. On the other
hand, a cut-off point of ≥10 is best for epidemiological
research, because it ensures a larger group of partici-
pants with possible depressive disorders, probably ran-
ging in severity. As a result, we recommend the
summed score of the PHQ-9 for screening for depres-
sion in diabetes patients in specialized outpatient clinics.
This is a reliable questionnaire which will subsequently
result in improving the quality of the patient’s life.
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